LeMaitre Vascular (NASDAQ:LMAT) Updates Q1 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its first quarter 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.640-0.690 for the period, compared to the consensus estimate of 0.620. The company issued revenue guidance of $65.6 million-$67.6 million, compared to the consensus revenue estimate of $65.9 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.810-3.010 EPS.

LeMaitre Vascular Trading Up 0.7%

NASDAQ:LMAT traded up $0.63 on Wednesday, reaching $91.38. The stock had a trading volume of 198,904 shares, compared to its average volume of 145,199. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $105.55. The firm’s fifty day moving average is $85.86 and its two-hundred day moving average is $88.09. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 39.39, a P/E/G ratio of 2.03 and a beta of 0.72. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Barrington Research reaffirmed an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Friday, February 20th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Roth Mkm reissued a “buy” rating and issued a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $100.20.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently modified their holdings of the stock. Royal Bank of Canada increased its stake in LeMaitre Vascular by 1.5% in the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after purchasing an additional 1,735 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after purchasing an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after buying an additional 539 shares in the last quarter. Millennium Management LLC grew its holdings in shares of LeMaitre Vascular by 119.8% during the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.